Maecker H T, Umetsu D T, DeKruyff R H, Levy S
Department of Medicine/Oncology, Stanford University Medical Center, CA 94305, USA.
Vaccine. 1997 Oct;15(15):1687-96. doi: 10.1016/s0264-410x(97)00088-1.
DNA vaccination may work through direct transfection of antigen presenting cells (APC), or by secretion of the encoded protein by muscle or skin cells for uptake by APC. If cytokines are attached to the antigen, they may influence APC or responding T cells to drive the response toward a Th1 or Th2 direction, and/or potentiate it in an antigen-specific manner. To test this concept, expression vectors were constructed containing the ovalbumin (OVA) gene either alone, or linked to cytokine genes including GM-CSF, IFN-gamma, IL-2, IL-4, IL-12, or a sequence encoding nine amino acids of IL-1 beta. These constructs expressed OVA-cytokine fusion proteins in vitro which retained cytokine bioactivity. C57BL/6 mice were injected intramuscularly with the DNA constructs. Little if any OVA-specific antibody was produced in response to any of the DNA constructs, except for OVA-IL-4. However, lymphocytes from BALB/c mice vaccinated with OVA-IL-12 and OVA-IL-1 beta constructs produced more IFN-gamma and less IL-4 during in vitro restimulation assays than did other groups. All constructs elicited OVA-specific cytotoxic responses which were maintained or even increased over 16 weeks. The OVA-IL-12 and OVA-IL-1 beta peptide constructs elicited the strongest cytotoxic responses at 2 weeks postinjection. Cytotoxic responses were seen in all animals, even those lacking OVA-specific Ab, and were not related to Ab level. These studies indicate that the humoral, cytokine, and cytotoxic responses to DNA vaccination can be effectively altered by certain cytokine fusion constructs.
DNA疫苗接种可能通过直接转染抗原呈递细胞(APC)发挥作用,或者通过肌肉或皮肤细胞分泌编码蛋白以供APC摄取来发挥作用。如果细胞因子与抗原相连,它们可能会影响APC或反应性T细胞,从而使反应朝着Th1或Th2方向发展,和/或以抗原特异性方式增强反应。为了验证这一概念,构建了表达载体,其单独包含卵清蛋白(OVA)基因,或与包括GM-CSF、IFN-γ、IL-2、IL-4、IL-12或编码IL-1β九个氨基酸的序列在内的细胞因子基因相连。这些构建体在体外表达OVA-细胞因子融合蛋白,且保留了细胞因子的生物活性。将DNA构建体肌肉注射到C57BL/6小鼠体内。除了OVA-IL-4外,对任何DNA构建体的反应几乎都没有产生OVA特异性抗体。然而,在用OVA-IL-12和OVA-IL-1β构建体接种的BALB/c小鼠的淋巴细胞在体外再刺激试验中比其他组产生了更多的IFN-γ和更少的IL-4。所有构建体都引发了OVA特异性细胞毒性反应,这种反应在16周内得以维持甚至增强。OVA-IL-12和OVA-IL-1β肽构建体在注射后2周引发了最强的细胞毒性反应。在所有动物中都观察到了细胞毒性反应,即使是那些缺乏OVA特异性抗体的动物,且细胞毒性反应与抗体水平无关。这些研究表明,某些细胞因子融合构建体可以有效地改变对DNA疫苗接种的体液、细胞因子和细胞毒性反应。